Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’

被引：0

作者：

Keisuke Imafuku

Koji Yoshino

Kei Yamaguchi

Satoshi Tsuboi

Kuniaki Ohara

Hiroo Hata

机构：

[1] Tokyo Metropolitan Cancer and Infectious Diseases Center,Department of Dermatology

[2] Komagome Hospital,Department of Dermatology

[3] Hokkaido University Graduate School of Medicine,undefined

来源：

British Journal of Cancer | 2017年 / 116卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：e14 / e14

共 50 条

[1] Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
Imafuku, Keisuke
Yoshino, Koji
Yamaguchi, Kei
Tsuboi, Satoshi
Ohara, Kuniaki
Hata, Hiroo
[J]. BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e14 - e14
[2] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
Bowyer, S.
Prithviraj, P.
Lorigan, P.
Larkin, J.
McArthur, G.
Atkinson, V.
Millward, M.
Khou, M.
Diem, S.
Ramanujam, S.
Kong, B.
Liniker, E.
Guminski, A.
Parente, P.
Andrews, M. C.
Parakh, S.
Cebon, J.
Long, G. V.
Carlino, M. S.
Klein, O.
[J]. BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
[3] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer
P Prithviraj
P Lorigan
J Larkin
G McArthur
V Atkinson
M Millward
M Khou
S Diem
S Ramanujam
B Kong
E Liniker
A Guminski
P Parente
M C Andrews
S Parakh
J Cebon
G V Long
M S Carlino
O Klein
[J]. British Journal of Cancer, 2016, 114 : 1084 - 1089
[4] Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
Bowyer, Samantha
Prithviraj, Prashanth
Lorigan, Paul
Larkin, James
McArthur, Grant
Atkinson, Victoria
Millward, Michael
Khou, Muoi
Diem, Stefan
Ramanujam, Sangeetha
Kong, Ben
Liniker, Elizabeth
Guminski, Alexander
Parente, Phillip
Andrews, Miles C.
Parakh, Sagun
Cebon, Jonathan
Long, Georgina V.
Carlino, Matteo S.
Klein, Oliver
[J]. BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e15 - e15
[5] Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
Samantha Bowyer
Prashanth Prithviraj
Paul Lorigan
James Larkin
Grant McArthur
Victoria Atkinson
Michael Millward
Muoi Khou
Stefan Diem
Sangeetha Ramanujam
Ben Kong
Elizabeth Liniker
Alexander Guminski
Phillip Parente
Miles C Andrews
Sagun Parakh
Jonathan Cebon
Georgina V Long
Matteo S Carlino
Oliver Klein
[J]. British Journal of Cancer, 2017, 116 : e15 - e15
[6] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
Prithviraj, Prashanth
McArthur, Grant A.
Atkinson, Victoria
Parente, Phillip
Andrews, Miles Cameron
Parakh, Sagun
Cebon, Jonathan S.
Klein, Oliver
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[7] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, Evan J.
Drake, Charles G.
[J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
[8] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
Reddy, Swathi B.
Possick, Jennifer D.
Kluger, Harriet M.
Galan, Anjela
Han, Dale
[J]. JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
[9] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
Robert, Caroline
Mateus, Christina
[J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
[10] Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
Savoia, Paola
Astrua, Chiara
Fava, Paolo
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (05) : 1092 - 1101

← 1 2 3 4 5 →